NLS Acquisition

This strategic investment unlocks new product offerings for Genovis to both existing and new customers and further paves the way for the expansion into new application areas, it states. Following the investment, Genovis will own 25 percent of Sequrna. As part of the transaction, the parties have agreed to a call option with an end […]

AddLife acquires BonsaiLab, a Spanish distributor in the field of cell and molecular biology. The company, with current revenues of EUR 8 million, has operations in Spain and Portugal and will be included in AddLife’s business area Labtech. BonsaiLab will be included in the Biomedical and Research business unit, a part of the Labtech business […]

Center for Translational Research (CTR) expands by acquiring Zelmic, the GMP-approved Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), specialized in development of topical and transdermal pharmaceutical formulations and drug delivery. The acquisition further expands CTRs portfolio, within pharmaceutical, regulatory, and clinical development to the CTR group, the company states. “The addition […]

Perpetua Medical has entered a letter of intent with the shareholders of ES-Medical regarding an investment in the company and acquisition of shares in ES-Medical. Perpetua Medical’s ownership is intended to amount to 70 percent of the shares in the company after the transaction, with an option to acquire the remaining 30 percent after three […]

Asahi Kasei Corp has announced that it will offer the shareholders of Calliditas Therapeutics to acquire the shares of the pharmaceutical company Calliditas for the purpose of making Calliditas a wholly-owned subsidiary of Asahi Kasei through a voluntary tender offer for Calliditas. In the Board’s opinion, the combination of Asahi Kasei and Calliditas will leverage […]

InDex Pharmaceuticals has entered into a conditional agreement to acquire all shares in Flerie Invest AB. Flerie will become a wholly-owned subsidiary of InDex Pharmaceuticals and Flerie’s shareholders will initially hold approximately 91.9% of the total number of shares and votes in the company, prior to the completion of the capital raise. As a result […]